Tools   Select Another Resource Report Type

https://www.cellhub.org/

Cell repository that aims to share cell samples for the scientific advancement of Type 1 Diabetes research. Cell lines can be requested from their cell bank inventory.

Proper citation: Helmsley Cellular Research Hub (RRID:SCR_015546) Copy   

•   Source: SciCrunch Registry

http://www.ndep.nih.gov/

Federal government public education program that promotes diabetes prevention and control. They aim to reduce the morbidity and mortality associated with diabetes and its complications. The NDEP is jointly sponsored by the National Institutes of Health and the Centers for Disease Control and Prevention and over 200 partner organizations. Target audiences include people with diabetes and those at risk, including the racial and ethnic populations disproportionately affected by the disease, health care providers and payers and purchasers of health care.

Proper citation: National Diabetes Education Program (RRID:SCR_001477) Copy   

•   Source: SciCrunch Registry

http://www.bsc.gwu.edu/dpp/protocol.htmlvdoc

Observational clinical trial studying the long term effect of diet and exercise and the diabetes medication, metformin, on the delay of type 2 diabetes in participants of the Diabetes Prevention Program (DPP). The Diabetes Prevention Program (DPP) was a multi-center trial examining the ability of an intensive lifestyle or metformin to prevent or delay the development of diabetes in a high risk population due to the presence of impaired glucose tolerance (IGT). The DPP has ended early demonstrating that lifestyle reduced diabetes onset by 58% and metformin reduced diabetes onset by 31%. The DPPOS is designed to take advantage of the scientifically and clinically valuable DPP participants. This group of participants is nearly 50% minority and represents the largest IGT population ever studied. Clinically important research questions remain that focus on 1)durability of the prior DPP intervention, 2) determination of the clinical course of precisely known new onset diabetes, in particular regarding CVD, CVD risk factors and atherosclerosis and microvascular disease, 3)close examination of these topics in men vs women and in minority populations. More than 87% of the original surviving DPP cohort has joined DPPOS as of December, 2007 and, to date, after 5 years of DPPOS and 10 years of combined DPP/DPPOS, 93% of the DPPOS cohort continue to attend annual follow-up visits. Interim analyses performed after 5 years of DPPOS have demonstrated a durable effect of diabetes prevention associated with the lifestyle and metformin interventions with 34 and 19% reductions in diabetes incidence, respectively, compared with the placebo group. Interim analyses also reveal significant reductions from baseline in CVD risk factors in the lifestyle intervention group, but with decreased utilization of glucose-lowering and lipid-lowering medications. Analyses of the participants in the placebo group who have developed diabetes during DPP/DPPOS, compared with those who have remained non-diabetic, reveal an increased frequency of retinopathy and microalbuminuria. The current, updated protocol describes the DPPOS including the revisions incorporated to complete the second five-years of the study. DPPOS participants have blood samples stored at the time of each annual visit. Specimens are stored at the study CBL until after the primary study outcomes are reported. DNA samples were previously collected and are stored at the NIDDKsample repository for DPP participants.

Proper citation: Diabetes Prevention Program Outcomes Study (RRID:SCR_001502) Copy   

•   Source: SciCrunch Registry

https://labnodes.vanderbilt.edu/community/profile/id/2228

THIS RESOURCE IS NO LONGER IN SERVICE. Documented on August 13,2025.Core facility that provides access to isolated pancreatic islets from normal and diabetic models and performs islet functional analysis. The IPA Core also provides solutions for high-resolution whole slide imaging and access to image analysis tools for quantitative assessment of pancreatic islet morphology.

Proper citation: Vanderbilt Diabetes Research and Training Center Islet Procurement and Analysis Core (RRID:SCR_000896) Copy   

•   Source: SciCrunch Registry

http://www.med.upenn.edu/idom/drc/cores/mouse.html

Core which provides researchers with resources for performing metabolic studies in mice. It also provides services, innovative techniques, and helpful consultation to both experienced and novice investigators with regards to metabolic questions.

Proper citation: Penn Diabetes Research Center Mouse Phenotyping Physiology and Metabolism Core (RRID:SCR_000888) Copy   

•   Source: SciCrunch Registry

http://www.t1diabetes.nih.gov/t1d-raid/index.shtml

NOTE: The T1D-RAID program is not currently accepting applications. Cooperative program that makes available, on a competitive basis, NCI resources for the pre-clinical development of drugs, natural products, and biologics to facilitate translation to the clinic of novel, scientifically meritorious therapeutic interventions for type 1 diabetes and its complications. A partial listing of those services includes: high-throughput screening, studies in animal models, formulation, pharmacology and toxicology studies, and bulk substances acquisition. Requests to T1D-RAID are brief (20 pages or less), and should clearly outline the resources required to ready the proposed therapeutic agent for clinical trials. T1D-RAID should enable entry into the clinic of promising molecules that are not otherwise likely to receive an adequate and timely clinical test. T1D-RAID is designed to accomplish the tasks that are rate-limiting in bringing discoveries from the laboratory to the clinic. Once a project has been approved, NIDDKstaff interact directly with the Principal Investigator (PI). NCI contractors perform the T1D-RAID-approved tasks under the direction of NIDDKand NCI staff. The required tasks will vary from project to project. In some cases T1D-RAID will support only one or two key missing steps necessary to bring a compound to the clinic; in other cases it may be necessary to supply the entire portfolio of development requirements needed to file an IND. Examples of tasks that can be supported by T1D-RAID include, but are not limited to: * Definition or optimization of dose and schedule for in vivo activity * Development of pharmacology assays * Conduct of pharmacology studies with a pre-determined assay * Acquisition of bulk substance (GMP and non-GMP) * Scale-up production from lab-scale to clinical-trials lot scale * Development of suitable formulations * Development of analytical methods for bulk substances * Production of dosage forms * Stability assurance of dosage forms * Range-finding initial toxicology * IND-directed toxicology, with correlative pharmacology and histopathology * Planning of clinical trials * Regulatory affairs, so that FDA requirements are likely to be satisfied by participating investigators seeking to test new molecular entities in the clinic * IND filing advice The output of T1D-RAID activities will be both products and information that will be made fully available to the originating investigator for support of an IND application and clinical trials. T1D-RAID does not sponsor clinical trials.

Proper citation: Type 1 Diabetes - Rapid Access to Intervention Development (RRID:SCR_000203) Copy   

•   Source: SciCrunch Registry

http://www.med.upenn.edu/idom/drc/cores/cellbio.html

Core that gives support including experimental design, islet isolation, and performance of and training in an expansive range of assays for physiological and morphometric assessment of pancreatic islet function and growth. It contributes to the basic and translational research activities of the Institute of Diabetes, Obesity and Metabolism (IDOM) at the Perelman School of Medicine of the University of Pennsylvania. Its services include perform individual islet and single cell fluorescence imaging, respirometry with islet batches using a Seahorse Extracellular Flux Analyzer, perifusion coupled with respirometry, and closed respirometry experiments for our investigators.

Proper citation: University of Pennsylvania School of Medicine Penn Diabetes Research Center Pancreatic Islet Cell Biology Core Facility (RRID:SCR_008265) Copy   

•   Source: SciCrunch Registry

http://www.einstein.yu.edu/centers/diabetes-translational-research/latino-network/

Research network dedicated to supporting translation research in diabetes prevention and control. The core has a strong emphasis on sociocultural adaption for Latinos in the U.S and can provide expertise in Latino biopsychosocial research.

Proper citation: New York Regional Center for Diabetes Translation Research Latino Network for Diabetes Translational Research (RRID:SCR_015189) Copy   

•   Source: SciCrunch Registry

http://www.einstein.yu.edu/centers/diabetes-translational-research/timc/

Core facility that supports research that addresses the prevention and control of diabetes using a social-ecological approach to address the dynamic interrelations of biological, psychological and social factor at a personal and environmental level.

Proper citation: New York Regional Center for Diabetes Translation Research Translational Intervention Methodology Core (RRID:SCR_015180) Copy   

•   Source: SciCrunch Registry

https://cdtr.wustl.edu/our-cores/communication-and-literacy/

THIS RESOURCE IS NO LONGER IN SERVICE. Documented on June 15,2026. Core facility whose services include assisting with outreach and recruitment to various populations, developing strategic community partnerships, and developing materials and methods for effective health education within the community.

Proper citation: Washington University Center for Diabetes Translation Research Health Communication and Health Literacy Core Facility (RRID:SCR_015198) Copy   

•   Source: SciCrunch Registry

http://clinicaltrials.gov/show/NCT00143949

Randomized, multicenter, double-blind study to determine if renin angiotensin medications, either losartan (angiotensin II blocker) or enalapril (converting enzyme inhibitor), can prevent or delay the onset of diabetic kidney disease in patients with type 1 diabetic patients who do not have hypertension, diabetic nephropathy, or predictive levels of microalbuminuria. Two hundred eight five patients ages 16-61 with 2-20 yrs of Type 1 Diabetes Mellitus and no renal functional abnormalities were randomized into a parallel, double-blind, placebo-controlled study involving 3 groups (95 patients/group). Each group received an angiotensin-converting enzyme inhibitor (ACEI) (enalapril), or an angiotensin II receptor blocker (Losartan), or placebo. All patients had their usual Diabetes Mellitus (DM) management. Baseline studies included measures of glomerular filtration rate (GFR), urinary albumin excretion rate (UAE), blood pressure (BP), and a percutaneous renal biopsy. Patients were followed by quarterly measures of BP, HbA1C, UAE, and drug compliance. There were annual measures of GFR and a repeat renal biopsy after 5 yrs in the study. The main endpoint is kidney structural changes over time, especially mesangial fractional volume (v(Mes/glom)). Secondary endpoints will be other DN structural measures and measures of kidney function (UAE, GFR). These studies will determine whether rennin angiotensin system blockage in the early stages of DN can prevent the early kidney structural changes in this important disorder. Ancillary studies will evaluate the effects of treatment group on the development and progression of diabetic retinopathy and will develop predictors of study participants'''' compliance. Baseline, 2.5 and 5 year retinal fundus photographs in the RASS patients were obtained.

Proper citation: Renin Angiotensin System Study (RRID:SCR_013385) Copy   

•   Source: SciCrunch Registry

https://cdtr.wustl.edu/our-cores/policy-and-systems-science-analysis/

THIS RESOURCE IS NO LONGER IN SERVICE. Documented on June 15,2026. Core facility whose services include policy consultation and research design advice, workshops on systems science analysis, and management of a resource library of policy and system science tools and datasets.

Proper citation: Washington University Center for Diabetes Translation Research Policy and Systems Science Analysis in Diabetes Research Core (RRID:SCR_015203) Copy   

•   Source: SciCrunch Registry

http://chicagodiabetesresearch.org/cores/

THIS RESOURCE IS NO LONGER IN SERVICE. Documented on June 30,2023. Core facility that provide support for diabetes translation research aiming to reduce health disparities and support translation research in the community.

Proper citation: Chicago Center for Diabetes Translation Research Health Disparities and Community-Based Participatory Research Core (RRID:SCR_015178) Copy   

•   Source: SciCrunch Registry

https://labnodes.vanderbilt.edu/resource/view/id/10414/collection_id/2234/community_id/1136

Core facility whose goal is to encourage and facilitate effective diabetes translation research among vulnerable minority populations, especially African and Hispanic Americans. They have three sub-units which include the Community-Based Participatory Research Unit/Planning Unit, the Behavioral Intervention Unit, and the Assessment, Design, and Analysis Unit. Services include a variety of assessments (psychological, dietary, community health surveys, physical activity) as well as research and implementation.

Proper citation: Vanderbilt Center for Diabetes Translation Research Community Outreach and Heath Disparities Core (RRID:SCR_015175) Copy   

•   Source: SciCrunch Registry

https://labnodes.vanderbilt.edu/resource/view/id/10409/collection_id/2234/community_id/1136

Core facility which offers services such as consultation of study design for community-based research, development of IRB protocols, usage of community resources for recruitment efforts, and access to community charcateristics data and geographic information on the community.

Proper citation: Vanderbilt Center for Diabetes Translation Research Community Engagement Core (RRID:SCR_015173) Copy   

•   Source: SciCrunch Registry

http://derc.yale.edu/cores/transgenic.aspx

Core facility which provides genetically modified mice and rodents, mainly transgenic and knockout mice and rodents in the NOD system. It also provides transgenic mice in F2 (usually B6/C3H) and rats on Sprague-Dawley, and chimeric mice using the 129 strain ES cells. It also provides training and management

Proper citation: Yale Diabetes Research Center Molecular Genetics Core (RRID:SCR_015145) Copy   

•   Source: SciCrunch Registry

http://www.ucdenver.edu/academics/colleges/PublicHealth/research/centers/CAIANH/cdtr/Pages/Administrative-Core.aspx

THIS RESOURCE IS NO LONGER IN SERVICE. Documented on January 30,2025. Administrative Core of the Center for American Indian and Alaska Native Diabetes Translational Research. The CAIANDTR is dedicated to extending prevention and management research of proven efficacy to both clinical and community settings, with the goal of improving the diabetes-related health of Native Americans.

Proper citation: Center for American Indian and Alaska Native Diabetes Translational Research Administrative Core (RRID:SCR_015148) Copy   

•   Source: SciCrunch Registry

http://www.med.upenn.edu/idom/drc/cores/metacore.html

Core which aims to develop and validate metabolomic methods and data analysis software and provide high quality routine metabolomic services. Its services include quantitation of selected water-soluble metabolites, fatty acids, and lipids, quantitation of metabolic fluxes using stable isotope tracers, and identification of novel metabolites involved in diabetes pathophysoiology.

Proper citation: Penn Diabetes Research Center Metabolomics Core (RRID:SCR_015122) Copy   

•   Source: SciCrunch Registry

http://www.ukbiobank.ac.uk/

Biobank provides data collected at Assessment Center and via online questionnaires on participants aged 40-69 years recruited throughout United Kingdom and provides summary information to improve prevention, diagnosis and treatment of serious and life threatening illnesses.

Proper citation: UK Biobank (RRID:SCR_012815) Copy   

•   Source: SciCrunch Registry

http://www.uab.edu/shp/drc/interventions-translational-core-links

THIS RESOURCE IS NO LONGER IN SERVICE. Documented on November 7,2024. Core which provides expertise and services that range from methods of intervention development, basic study design and data analysis, and cutting-edge methodologies in measurement, to subject recruitment and retention strategies with an emphasis on increasing minority participation.

Proper citation: University of Alabama at Birmingham Diabetes Research Center Interventions and Translation Core (RRID:SCR_015135) Copy   

•   Source: SciCrunch Registry